Agiomix, the next generation genomics company, has announced the appointment of Dr John Clarkson as chairman with immediate effect.
Dr Clarkson joins Agiomix with 20 years’ experience of developing commercial diagnostics and life science tools.
He has held a number of senior commercial and technical leadership positions within both public and private companies.
Most recently, Dr Clarkson was the founding CEO of the molecular diagnostics company, Atlas Genetics, where he remains a non-executive director.
During his tenure at Atlas Genetics, Dr Clarkson raised $90 million with multiple fundraising to fund the development of the rapid io diagnostic platform for infectious diseases from concept through to regulatory approval.
Atlas Genetics is backed by the corporate venture funds of Novartis and Johnson & Johnson amongst other investors.
Prior to this, Dr Clarkson was co-founder and Commercial Director of Molecular Sensing, a rapid DNA analysis company, which was acquired by Osmetech.
Dr Clarkson has a degree and PhD in genetics and prior to moving into the life science industry, was a faculty member and senior lecturer at the University of Bath, UK where his research group focused on the biochemistry and molecular biology behind the mechanisms of microbial pathogenesis.
Dr Clarkson said: “I am delighted to be joining Agiomix at this exciting stage in its development. As a company at the forefront of developing the next generation of genomics tools, Agiomix is bringing a wide range of sequencing, genotyping and bioinformatics services to the research and clinical communities in emerging markets."
"These services are underpinned by our first-class facilities and clinical support and I look forward to working closely with the team here as we build a reputation as a leader in this multi-million-dollar market.”
About Agiomix FZ-LLC:
Agiomix FZ-LLC is a Dubai-headquarterd genomics company, focused on offering sequencing and genotyping services to the research and clinical communities in the emerging markets. Agiomix aims to offer localized, high standard and affordable genomics services throughout the Middle East, Africa and Asia. The company’s philosophy is to offer services coupled with high level of genetic counselling and support for its customers, and its business model targets expansion to key markets to become customers’ preferred “next-door genomics partner”.
© Press Release 2018
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
